IL6R and graft versus host disease: Inhibition of classical signaling of IL-6R on donor T cells decreased the severity of Th17 and Th22-dependent GVHD without inhibiting GVL response against a primary blast crisis chronic myeloid leukemia cell line BCR-ABL/NUP98-HOXA9 (88).